Miruvor
Sign up
The short answer

What studies of antidepressants (unspecified) found

27papers on antidepressants (unspecified)
15,632patients in 1 health-record study, counted apart from trials
0randomised trials, the strongest kind of study

At a glance, by condition

Preventing long COVID: D Little or no difference

Based on the strongest evidence, compared with another group, not randomised (very low certainty), for low mood or anxiety.

1 outcome rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with antidepressants (unspecified) for preventing long COVID. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects and all 27 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Antidepressants (unspecified) · Preventing long COVID is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

Preventing long COVID

Low mood or anxiety1 study · 15,632 people took antidepressants (unspecified) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); the change wasn't shown to be more than chance.

Compared with another group, not randomised18,620 in the study · 31,264 with outcome data · 3–6 and 3–12 months after the index SARS-CoV-2 infection · within one month prior to their first recorded COVID-19 diagnosis

No clear difference in low mood or anxiety.

The evidence is very uncertain about the effect of antidepressants (unspecified) on low mood or anxiety later, when given during acute COVID. Little or no difference · very low certainty D

  • Serious risk of bias (ROBINS-I)
  • The change wasn't shown to be more than chance
See the 1 study
  1. Associations of selective serotonin reuptake inhibitors and long COVID risk in patients with depression: a retrospective cohort study. (2026)

    People in the study
    18,620 in the study · 31,264 with outcome data
    Dose
    within one month prior to their first recorded COVID-19 diagnosis
    Outcome
    depression or anxiety symptoms
    Effect
    no clear difference
    Risk of bias
    ROBINS-I: Serious
    Confounding
    Moderate. comparison group: Patients with depression prescribed non-SSRI antidepressants during the same pre-infection window; propensity-score matched. demographics (age, sex, and ethnicity), socioeconomic factors (education level, employment status, social and psychosocial environment, and housing conditions), problems related to lifestyle, and psychiatric comorbidities
    Selection of participants
    Moderate. comparison group: Patients with depression prescribed non-SSRI antidepressants during the same pre-infection window; propensity-score matched. The non-SSRI antidepressant group comprised patients prescribed other antidepressants during the same pre-infection window.
    Classification of interventions
    Moderate. from records after the fact
    Deviations from intended interventions
    NI. not reported for this design
    Missing data
    NI. missing data aren't reported
    Measurement of outcomes
    Serious. self-reported by people who knew their treatment
    Selection of the reported result
    Serious. a exploratory result

Side effects

No study of this treatment alone reported side effects we could read.

All papers

  1. Effect of psychological and behavioral intervention on the rehabilitation of patients with chronic fatigue syndrome2016 · randomised trial · 71 randomised
    Summary

    This prospective, single-blind study enrolled 71 outpatients diagnosed with chronic fatigue syndrome according to the criteria of the U.S. Centers for Disease Control. Participants were divided randomly by coin method into a group receiving systematic psychological and behavioral intervention (31 cases) and a control group receiving antidepressant drug treatment only (40 cases). The Chronic Fatigue Assessment Scale (FAI) was used to estimate clinical efficacy. The paper does not report treatment duration, follow-up length, or the number analysed. In the psychological and behavioral intervention group, each FAI factor score was reported as significantly improved after treatment: S (3.20±1.72), SS (4.01±1.32), PC (4.95±1.82) and RTR / S (6.02±1.59) (P 0.05). Total improvement was not clear (P>0.05). The total effective rate was significantly higher than that of the control group. Compliance results showed no falling off in the psychological behavior intervention group and 8 cases to fall off in the control group. Psychological and behavior intervention treatment efficacy and disease course, <12 months in patients with good effect. Harms were not reported. The authors' conclusion is given separately.

  2. Associations of selective serotonin reuptake inhibitors and long COVID risk in patients with depression: a retrospective cohort study.2026 · compared with another group · 18,620 in the study · 31,264 with outcome data
    Summary

    This retrospective cohort study used U.S. electronic health records from TriNetX to examine whether SSRIs were associated with long COVID risk in adults with depression and documented COVID-19. Before matching, the primary cohort included 18,620 patients prescribed SSRIs and 20,833 patients prescribed non-SSRI antidepressants; prescriptions were recorded within one month before the first COVID-19 diagnosis. After propensity score matching, 31,264 patients were included, with 15,632 in each group. The study compared SSRIs with non-SSRI antidepressants. Outcomes were long COVID diagnosis (ICD code U09.9) and CDC-defined long COVID symptoms at 3–6 and 3–12 months after the index SARS-CoV-2 infection. For long COVID diagnosis, the hazard ratios were 0.57 (95% CI: 0.44–0.73) at 3–6 months and 0.59 (95% CI: 0.49–0.72) at 3–12 months. For CDC-defined symptoms, the hazard ratios were 0.79 (95% CI: 0.73–0.87) and 0.85 (95% CI: 0.81–0.89) at 3–6 and 3–12 months. Patients prescribed SSRIs had a lower risk of neurological symptoms and joint or muscle pain than those receiving non-SSRI antidepressants, but not depression or anxiety symptoms. No significant difference in long COVID risk was observed between S1R agonist SSRIs and other SSRIs without S1R agonist activity. Harms were not reported. The authors state that residual confounding and biases mean causality cannot be established; the ICD-10 U09.9 code became available only in October 2021 and underestimated long COVID incidence; SSRI dose, duration, and adherence could not be ascertained.

  3. SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative.2026 · compared with another group · 110,955 in the study
    Summary

    This retrospective cohort study used electronic health record data from 37 US health systems in the RECOVER Initiative. It included 110,955 children and adolescents aged 5–20 years with documented SARS-CoV-2 infection and pre-existing neuropsychiatric conditions. Of these, 12,416 were SSRI/SNRI users and 98,539 were nonusers. SSRI/SNRI exposure was defined as treatment from 28 days before to 28 days after the index date. Long COVID outcomes were assessed 28–179 days after infection. Among SSRI/SNRI users, 90.7% received SSRIs and 9.3% received SNRIs. The clinician-recorded long COVID diagnosis code U09.9 was recorded in 1.13% of SSRI/SNRI users and 0.79% of nonusers; adjusted analysis showed no significant association (RR 1.12, 95% CI 0.92–1.36). Any of 23 predefined long COVID symptoms/conditions occurred in 10.13% of SSRI/SNRI users and 18.14% of nonusers, with a higher adjusted RR of 1.56 (95% CI 1.23–1.99). Reduced risks were observed for fever and chills (RR 0.86, 95% CI 0.75–0.99) and hair loss (RR 0.69, 95% CI 0.49–0.96). Increased risks were observed for thromboembolic events (RR 1.93, 95% CI 1.35–2.77), cognitive dysfunction (RR 1.84, 95% CI 1.39–2.43), POTS (RR 1.33, 95% CI 1.18–1.51), abnormal liver enzymes (RR 1.33, 95% CI 1.02–1.73), fatigue and malaise (RR 1.20, 95% CI 1.07–1.34), generalized pain (RR 1.19, 95% CI 1.05–1.35) and abdominal pain (RR 1.13, 95% CI 1.03–1.25). The paper does not report harms, side effects, adverse events or discontinuations for either group. The authors state that the retrospective design and reliance on EHR data may lead to misclassification of infection status or outcomes and that residual confounding is possible.

  4. An investigation of the long-term benefits of antidepressant medication in the recovery of patients with chronic fatigue syndrome.2006 · compared with another group · 275 in the study
    Summary

    This longitudinal study asked whether antidepressant medication prescribed at referral was associated with recovery in Chronic Fatigue Syndrome (CFS). Two hundred and seventy-five patients fulfilling CDC criteria, attending a dedicated outpatient clinic, completed measures at baseline, 6 months, 18 months and 3 years. Twenty-three patients were in the SSRI group, 26 in the tricyclic group, and 226 in the no-antidepressant group; dose, duration and specific drugs were not reported. Groups were compared on recovery using the current state of health measure, a 28-item symptom checklist, the PFRS fatigue sub-scale, sleep quality, activity levels, and anxiety/depression measures. The SSRI and tricyclic groups combined had recovery rates of 10.5% at 6 months versus 2% with no antidepressants, and 29.2% at 3 years versus 6%; the 3-year recovery comparison reached p < 0.03. At 3 years, 43% of the SSRI group, 10% of the tricyclic group and 6% of the no-antidepressant group were rated almost completely recovered (p < 0.005). Total symptom scores were lower in the antidepressant group than the no-antidepressant group at 18 months and 3 years; individual symptom reporting, sleep and activity also showed differences favouring the SSRI group. There were no significant improvements in psychopathology. Side effects and withdrawals were not reported. The authors state limitations including retrospective design and unavailable intervention length, dosage and specific drugs.

  5. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome.2014 · no comparison group · 76 in the study
    Summary

    Seventy-six ME/CFS patients admitted to the Maes Outpatient Clinics, Belgium, were selected for increased (> 2 SD) IgM responses to 3 OSEs or 3 NO-adducts. In this non-interventional study, all patients took a combination of NAIOS—L-carnitine, coenzyme Q10, taurine + lipoic acid, with or without curcumine + quercitine or N-acetyl-cysteine, zinc + glutamine—continued for 14.3 (±4.2) months. There was no separate comparison group; patients also received other care-as-usual treatments. The study measured FF scores and IgM responses to oleic acid, MDA, Pi, NOW, NO-arginine and NO-cysteinyl. Treatment was followed by significant reductions in IgM responses to oleic acid (F=9.03, p=0.004), MDA (F=13.12, p=0.001), Pi (F=20.28, p<0.001), NO-Cysteinyl (F=10.03, p=0.003), NO-Arginine (F=6.99, p=0.011) and NOW (F=6.19, p=0.016). In patients with endpoint FF<12, oleic acid and Pi responses fell more than in those with endpoint FF≥12. Antidepressant use had no significant effect (F=0.17, p=0.843). Harms were not reported. The authors state the non-interventional design could not standardize NAIOS and that supplement quality, content and bioavailability may have biased results.

  6. A novel frameshift mutation in ADCK1 identified in a case of chronic fatigue syndrome successfully treated with oral 5-ALA/SFC.2025 · case report · 1 in the study
    Summary

    This case report describes one 35-year-old Japanese woman with Chronic Fatigue Syndrome (CFS) who had experienced chronic fatigue since the age of 11 years. No comparison group was reported; the report describes a within-person clinical course over four years. The patient was treated with modafinil and methylphenidate beginning in 2012, levocarnitine at 1500 mg daily from November 2018, ubiquinone at 30 mg/day, and oral 5-ALA/SFC starting at 100 mg/day in January 2021. The 5-ALA/SFC dose was increased by 200 mg daily in February, to 300 mg/day in April 2021, and to 400 mg/day in January 2022; later attempts to reduce the dose in August 2022 to 200, 100, and 50 mg resulted in a significant decline in various activities. Outcomes included daily activities, mobility, psychosocial functioning, symptoms and quality of life, FACIT-F scores over time, daytime activity, daily functioning, various activities, sleep disturbances, and depression symptoms. The report states that 5-ALA/SFC led to significant improvements in daily activities, mobility, and psychosocial functioning; that the treatment regimen augmented with 5-ALA/SFC and ubiquinone led to significant improvements in symptoms and quality of life; and that returning to the 400 mg dose markedly improved all scores. Modafinil and methylphenidate proved ineffective for sleep disturbances, and antidepressants failed to improve depression symptoms. The patient continued 5-ALA/SFC for 4 years with no apparent adverse events; mild fever and chest discomfort were also reported. No withdrawals due to harms were recorded. Limitations include unavailable paternal DNA, uncertainty about the heterozygous mutation and CFS, and unclear long-term safety of 5-ALA/SFC.

  7. [Sleep disorders and fatigue syndrome in long COVID syndrome: case-based experiences from neurological/sleep medicine rehabilitation].2022 · case report · 4 in the study
    Summary

    Four case examples from a neurological/sleep medicine rehabilitation clinic described adults after COVID-19 with Long-COVID/Post-COVID symptoms. The report included one 30-year-old woman, one 48-year-old woman, one 18-year-old and one 31-year-old; no comparison group and no randomisation were reported. Treatments were multimodal and individual: movement/sport/physiotherapy and slowly built circuit training in Fall 1 over seven weeks, plus melatonin 2 mg retardiert in the evening; neuropsychological therapy, sport therapy with circuit training, light walking and increasing walking distance in Fall 2 over eight weeks, plus regular melatonin 2 mg retardiert; sport, physiotherapy, ergotherapy and low-dose Mestinon plus antidepressants in Fall 3 over ten weeks; physiotherapy, ergotherapy, speech therapy, lamotrigine 50 mg and valproic acid 300 mg 3× daily in Fall 4 during a twelve-week stay. Reported outcomes included physical performance, heart rate, sleep fragmentation, sleep quality, neuropsychological tests, subjective performance, hypersensitivity and sleep-onset insomnia. Fall 1 reported improvement over seven weeks, heart rate reduction to 64/min and 80% improvement of baseline symptoms; sleep fragmentation reduced after three weeks of melatonin and sleep quality was satisfactory after six weeks. Fall 2 reported increased physical performance within eight weeks, return to 70% of baseline performance, and improved insomnia with melatonin. Fall 3 reported no substantial clinical improvement after ten weeks. Fall 4 reported improved hypersensitivity within ten weeks and complete resolution of sleep-onset insomnia within the twelve-week stay. Harms and withdrawals were not reported.

  8. Successful Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome with Chronic Febricula Using the Traditional Japanese Medicine Shosaikoto.2020 · case report · 1 in the study
    Summary

    This case report describes one 14-year-old girl with ME/CFS and chronic intermittent febricula who had experienced fatigue, febricula and social withdrawal for 20 months and was referred to the authors' department. There was no comparison group; changes are reported before versus after treatment in the same patient. She was prescribed shosaikoto 6.0 g per day; 6.0 g of orengedokuto was later added to SST for low-grade fever and fatigue. Six weeks after the first consultation, ogikenchuto 18 g/day replaced OGT for appetite loss and fatigue, and tokishakuyakusan 5.0 g daily later replaced SST. A psychiatrist prescribed paroxetine for five weeks, but her symptoms did not improve and it was tapered and discontinued. The performance status score was 6 at baseline and decreased to grade 1 when she returned to school. The authors report alleviation of several symptoms two weeks later, resolution of malaise, intermittent fever and sleep disturbance at six weeks, mostly resolved ME/CFS symptoms at seven months, and almost symptom-free status sixteen months after the first consultation, when all Kampo treatments were terminated. No adverse effects of Kampo treatment were observed. The authors state no limitations.

  9. [A case of chronic fatigue syndrome who showed a beneficial effect by intravenous administration of magnesium sulphate].1992 · case report · 1 in the study
    Summary

    The report describes one 29-year-old female with chronic fatigue syndrome, diagnosed using the working case definition proposed by Holmes et al., who was transferred to the authors' hospital in May 1991. The text says she had been treated for atopic dermatitis for 5 years. She had general malaise, low grade fever, lymph node swelling, headache, myalgias, muscle weakness, arthralgias and insomnia. Magnesium sulphate was given intravenously once a week for about 6-week's administration, with the aim of improving her condition, especially severe general malaise. There was no comparison group; the report describes a before-and-after course in this one patient. After about 6-week's administration of magnesium sulphate, she noticed reduced easy fatigability and an improvement in her impaired daily activities. Finally she was able to leave the hospital in January 1992. The abstract reports no side effects, no withdrawals and no worsening. No formal scale for easy fatigability or daily activities is reported, and no p-values or statistical comparisons are reported. The authors state no limitations in the abstract.

  10. Chronic fatigue syndrome after neuroborreliosis in farmers from Lublin region (Poland)2007 · combination: given with other treatments · 48 in the study
  11. [The Impact of Antidepressants on COVID-19 and Post-Acute COVID-19 Syndrome: A Scoping-Review Update].2026 · systematic review
    Summary

    This systematic scoping review searched PUBMED on May 20, 2024 and identified 1016 articles related to antidepressants and COVID-19, Long COVID and SARS-COV-2. It included 10 retrospective “large scale” studies (> 20000 chart reviews), 8 prospective clinical trials (plus 4 regarding Long COVID), 11 placebo-controlled randomized (RCT) (plus 2 regarding Long COVID) and 15 meta-analyses. The review reports retrospective studies of antidepressants, most studied SSRIs and SSNRIs, associated with significantly fewer SARS-COV-2 infections and a milder course of COVID-19. 12 out of 15 meta-analyses referred to fluvoxamine and found a significant (40-70% reduction) in mortality, intubation and hospitalization rates when fluvoxamine was used as an add-on to standard therapy for mild to moderate COVID-19. A dose dependency was observed: 2x50 mg fluvoxamine over 15 days was less effective than 2x100 or even 3x100 mg, with an adverse event profile still at the placebo level. An indirect meta-analytical comparison showed an advantage of paxlovid or molnupiravir versus fluvoxamine: risk reduction of 95% or 78% versus 5+-5%. An add-on of fluvoxamine was still significantly more efficacious than symptom-oriented standard therapy alone. For Long COVID, a phenotype with anxiety and depression symptoms responds to AD, relaxation therapy and/or psychotherapy; casuistics report positive effects of AD on fatigue, cognitive and autonomic dysfunctions. A first large prospective open-label RCT showed significantly more favourable courses, less viral load and less pro-inflammatory cytokines with fluvoxamine versus standard treatment, also regarding subsequent neuropsychiatric and pulmonary Long COVID or fatigue. Worsening and discontinuation counts were not reported.

  12. Guiding future research on psychological interventions in people with COVID-19 and post COVID syndrome and comorbid emotional disorders based on a systematic review.2023 · systematic review
    Summary

    This systematic review asked what psychological interventions have been studied in people with COVID-19 or long COVID-19 and comorbid emotional disorders. Searches were run in WOS, Scopus, PubMed, PsycINFO, Cochrane and CINAHL on June 14, 2023. The review included 43 studies with 2,359 adults; only three studies included long COVID-19 patients. Interventions included CBT and psychotherapy, meditation/yoga/breathwork, trauma work such as EMDR, and other approaches. Some studies had control groups, for example Cengiz (Control = 22; intervention = 22), Kong (control = 13; intervention = 13), and Mahendru (control = 42; experimental = 42); others were pre-post without control. Outcomes included anxiety, depression, stress, insomnia, PTSD, and COVID-19 fears. Findings were mixed. Cengiz reported no statistically significant difference between groups at post assessments (p > 0.050). Mahendru found no significant differences in anxiety (mean control = 1.81, mean intervention = 2.14, p = 0.528) but significant differences in depression and stress. Won reported no significant improvements in PHQ-9 and GAD-7 (p > 0.050), with a significant reduction in PTSD symptoms (p = 0.041). In Alkhamees, 2021, 1 participant dropped out of CBT after the 2nd visit. No side-effect counts were recorded. The authors describe promising results but note important limitations.

  13. What treatments work for anxiety and depression in children and adolescents with chronic fatigue syndrome? An updated systematic review.2022 · systematic review
    Summary

    This systematic review updated searches from 2015 to 2020 in Cochrane Library, Medline, Embase and PsycINFO for studies of children and adolescents with CFS/ME and validated measures of depression and/or anxiety. Combined with previous reviews, 16 studies and 965 participants were included; follow-up ranged from immediately post-treatment to 21 years. Treatments included CBT, the Lightning Process, valacyclovir, pacing, gammaglobulin, placebo, and inpatient or specialist care programmes. An RCT compared Lightning Process plus specialist medical care with specialist medical care alone; the review reports adjusted mean differences in depression and anxiety scores at 6 and 12 months, for example depression −1.5 (−3.5 to 0.5, 0.1) at 6 months and −1.8 (−3.4 to −0.1, 0.04) at 12 months. An observational cohort of routine specialist care measured depression and anxiety at baseline but not post-treatment. CBT-type interventions had most evidence for improving comorbid anxiety and/or depressive symptoms, but delivery and modality varied. A trial reported a deterioration in school attendance in the pacing arm. The review reports insufficient evidence to draw conclusions, and no study specifically targeted depression or anxiety. The authors state the evidence is poor and insufficient for meta-analysis.

  14. Acupuncture Treatment for Chronic Fatigue Syndrome2019 · systematic review
    Summary

    This chapter systematically reviewed acupuncture treatment for chronic fatigue syndrome (CFS) based on a broad literature search and the authors’ experiences. It reports 40 clinical research papers on acupuncture for CFS published over the last 10 years. The reviewed studies used simple acupuncture, electro-acupuncture, blood-letting acupuncture, acupoint application, acupoint catgut embedding, acupoint injection, auricular acupuncture, abdominal acupuncture, moxibustion, cupping and combined therapies. Examples include 32 CFS patients given acupuncture at acupoints versus non-meridian points, measured with the WHOQOL-BREF; 60 cases randomly divided into electro-acupuncture on acupoints or non-acupoints, 30 cases in each group, measured with FSS, SPHERE, VAS and SF-36, with the acupoints group reported better (P < 0.01); and 180 CFS patients randomly divided into 2 groups (92 treatment, 88 control) for acupoint injection. Reported rates included a total effective rate of 93.75% for electro-acupuncture plus auricular application, a total efficiency of 96.7% for auricular acupuncture in 60 cases, and a total efficiency of 94.34% for abdominal acupuncture. A reviewed RCT found no obvious difference between a low sugar low yeast diet and healthy eating. The harms text states auricular acupuncture with acupoint catgut embedding has fewer clinical side effects than traditional acupuncture, while excessive exercise may lead to immune function disorders and may aggravate CFS symptoms. Numbers who worsened or stopped were not reported. The authors state current research lacks a unified syndrome differentiation standard and a unified evaluation standard of efficacy.

  15. Chronic fatigue syndrome.2011 · systematic review
    Summary

    This systematic review asked what the effects of treatments for chronic fatigue syndrome are. The authors searched Medline, Embase, The Cochrane Library and other databases up to March 2010, included 46 systematic reviews, RCTs or observational studies, and rated the quality of the evidence with GRADE. They list the treatments covered: antidepressants, cognitive behavioural therapy, corticosteroids, dietary supplements, evening primrose oil, galantamine, graded exercise therapy, homeopathy, immunotherapy, intramuscular magnesium, oral nicotinamide adenine dinucleotide and prolonged rest. The abstract gives no finding for any of them and names no included study, so no results are listed here.

  16. Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): diagnosis and management.2025 · review
    Summary

    This narrative review searched PubMed, Web of Science, Embase, and the Cochrane Library from inception to August 2025 and included 211 publications on ME/CFS diagnosis, pathophysiology, assessment, and treatment. It summarized pharmacological and non-pharmacological interventions. Reported examples include a double-blind, randomized, placebo-controlled trial of IVIG in 99 CFS patients that found an absence of dose-dependent efficacy; a Phase III rintatolimod study in 208 ME/CFS patients in which 51.2% of a severely debilitated subgroup (n = 21/41) had a ≥ 25% improvement in exercise treadmill test duration; a 12-week trial in 207 ME/CFS patients reporting significant reductions in fatigue with CoQ10 (200 mg) and nicotinamide adenine dinucleotide (20 mg); LDN showing significant improvement in 73.9% of 218 ME/CFS patients; and a pilot study of 55 ME/CFS patients in which oral minocycline produced favorable symptom improvements for 80% of treatment completers. A pooled analysis of 1,298 ME/CFS patients from eight trials associated CBT with significant reductions in fatigue severity and functional impairment. A pragmatic trial in 241 adolescents (aged 8–17) found no significant inter-group difference between GET and activity management for physical function on the Short-Form 36 at 6 months. A systematic review and meta-analysis reported a significant reduction in fatigue (Hedges’ g = -0.52) and an improvement in physical function with pacing compared with no treatment or routine care. Harms included GET-associated symptom exacerbation in a significant proportion of patients, and rintatolimod adverse events may occur. TCM findings should be cautiously interpreted because the available evidence is constrained by methodological limitations.

  17. Health care for patients with long COVID: a scoping review.2024 · review
    Summary

    This scoping review examined health care for patients with Long Covid-19. It included 13 studies identified in electronic databases, carried out in several countries and published in English. Included studies reported telerehabilitation with physical exercises, physical exercise interventions, outpatient pulmonary rehabilitation, standard physical therapy, cognitive behavioral therapy with antidepressants and non-benzodiazepine tranquilizers, and supervised concurrent training with or without inspiratory muscle training; an exercise intervention was reported at 8 weeks. Some studies compared supervised therapeutic exercise with a WHO self-management rehabilitation leaflet, physical training rehabilitation with standard physical therapy, and physical exercise with breathing training and controls. Outcomes included physical capacity, quality of life, symptoms, fatigue, dyspnea, and stress, anxiety and depression. The review reports improvements after telerehabilitation in physical capacity, quality of life, fatigue and dyspnea; improvement in fatigue after physical intervention; reduction in dyspnea after 8 weeks of physical exercise; increase in 6-minute walk distance and decrease in dyspnea after outpatient pulmonary rehabilitation; maximum inspiratory mouth pressure increased by 28%; MDP score after physical training rehabilitation was 42% lower than after standard physical therapy; and improvement in stress, anxiety and depression with CBT plus antidepressants and tranquilizers. It also reports that some fatigue and quality of life results did not show significant improvements compared to the control group, and that participants reported relapses when performing physical exercise. No side-effect counts were reported. The authors state the selected studies did not provide specific guidelines and that there is a clear gap in the literature on how to identify and clinically manage people with this condition.

  18. Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases2024 · review
    Summary

    This paper is an Opinion review, not a primary study; it reports no own participants, location, treatment duration, or primary outcome. It summarizes literature found in pubmed as of 09/25/2023: five prospective studies (plus 2 for Long COVID), 7 RCT (plus 2 for Long COVID) and 12 meta-analyses. The review discusses antidepressants for prevention of severe COVID-19 and Long COVID. In its Long COVID table, named entries include fluvoxamine (2 × 50 mg) for Bramante et al. 2022, marked 0; fluoxetine for Farahani et al. 2023, marked (+) Fluoxetine (Fatigue); vortioxetine for Di Nicola et al. 2023, marked +; tricyclic AD for La Sala et al. 2023, marked + Tricyclic AD (2 Cases); AD for Fontera et al. 2022, marked +; SSRI for Rus et al. 2023 (N = 95), marked +; and SSRI for Sidky et al. 2023 (N = 17,933; preprint), marked +. For harms, the review states tolerability of AD was reported to be generally well across prospective, randomized controlled studies and meta-analyses presented in the table. Siripongboonsitti et al. 2023 is noted with no deaths in both the fluvoxamine and control group. The authors describe Long COVID evidence as limited but with first preliminary promising results for AD. The paper itself does not compare arms; it tabulates named studies, including placebo-controlled randomized studies. The recorded data do not report people who worsened or stopped.

  19. Research progress on pathogenesis of chronic fatigue syndrome and treatment of traditional Chinese and Western medicine.2024 · review
    Summary

    This comprehensive review synthesized recent literature on Chronic Fatigue Syndrome (CFS) pathogenesis and traditional Chinese and Western medicine treatments; it did not enroll or analyze its own patient cohort, so setting was not reported. Cited studies described varied interventions. Shu et al. randomized 30 CFS patients to acupuncture or moxibustion at Zusanli and Guanyuan; after 4 and 10 weeks both alleviated fatigue symptoms by modulating the vagus nerve, with acupuncture showing superior short-term and moxibustion enhanced long-term clinical efficacy. Luo et al. studied 60 female CFS patients receiving 30-min or 60-min moxibustion three times per week for four weeks; 60-min moxibustion showed advantages for fatigue and depression. Qi Fengjun et al. allocated 60 CFS patients to massage or acupuncture for two treatment courses each lasting 10 days; massage showed significant therapeutic benefits. Liang Weili et al. divided 70 CFS patients; oral medication plus herbal-cake moxibustion was more efficacious than oral medication alone for fatigue and sleep quality. Borody et al. reported FMT therapeutic efficacy in 70% of cases (42 out of 60) with gastrointestinal symptoms. Adamson et al. observed improvement in 995 CFS patients after cognitive-behavioral and psychological interventions. Harms included lower incidence of nausea and diarrhea with moxibustion plus paroxetine than paroxetine alone; in a Norwegian survey approximately 80% of patients reported decline in health status after graded exercise therapy. The authors stated limitations including lack of rigorous trial design and safety data.

  20. What interventions or best practice are there to support people with Long COVID, or similar post-viral conditions or conditions characterised by fatigue, to return to normal activities: a rapid review2023 · review · preprint
    Summary

    This rapid review asked what interventions or best practice support people with Long COVID, or similar post-viral conditions characterised by fatigue, to return to normal activities. It included ten relevant studies published between 2014 and 2022: systematic reviews, primary studies and guidelines. The primary studies covered Long COVID and CFS. One survey of 145 UK workers recovering from COVID-19 found that only 15% managed a full return to work. A longitudinal cohort of 111 patients with CFS after mononucleosis described a written self-management programme; there was an 18% increase in patients in employment from baseline (10% in employment) to follow-up (28% in employment). A case study of 1 patient with Long COVID reported improved depression and anxiety symptoms and improved quality of life and work and social adjustment after management therapy. A qualitative study of 8 healthcare professionals reported gradual return to work as a frequently mentioned accommodation. The reviews reported that exercise therapy, electrical nerve stimulation, sleep and touch therapy, and behavioural self-management may be beneficial; in one review exercise therapy may have a positive effect on fatigue compared with usual care or passive therapies. Four of five interventions in one review found statistically significant benefit, while music therapy combined with CBT reported no significant benefit. Side effects were not counted; one review was uncertain about the risk of side effects. The authors state little reported evidence of effectiveness and weak overall evidence.

  21. Cognitive behavior therapy for chronic fatigue syndrome: efficacy and implications.1998 · review
    Summary

    This review examined cognitive behavior therapy (CBT) for chronic fatigue syndrome (CFS). Butler et al. 1991 (case series, 32 patients) reported that a rehabilitative behavioral form with a mean of 8 sessions was followed by improvement from baseline in fatigue, disability, and depression; the table notes 18 patient refusals and 5 dropouts. Lloyd et al. 1993 (randomized controlled trial; 41 1 49 patients) compared a brief rehabilitative form (6 individual sessions) with medical care and found no difference in functional impairment at 3 months. Sharpe et al. 1996 (randomized controlled trial; 30 1 30; 60 patients recruited) compared 16 individual sessions with medical care: approximately three quarters of CBT patients had a good outcome at 12 months versus one quarter with medical care alone, fatigue, self-rated disability, depression, and timed walking distance improved more with CBT, and no patients dropped out. Deale et al. 1997 (30 1 30) compared 13 individual sessions with 13 relaxation sessions and found greater reduction in disability, fatigue, and depression at 6 months. A separate randomized trial found graded increases in activity substantially more effective than flexibility exercises for disability and symptoms; patients were not harmed or made worse, while another graded exercise trial in unselected patients had a high refusal and dropout rate. The authors state there is now good evidence from 2 independent randomized clinical trials to support CBT efficacy, that the treatment effect is substantial although few patients are cured, and that intensive individual CBT remains the treatment of choice.

  22. Chronic fatigue syndrome. 2: Treatment and future research.1995 · review
    Summary

    This narrative review discusses treatment approaches for CFS and offers a suggested clinical approach based on available research data and anecdotal clinical experience; it reports no study of its own. It describes a British study of 32 CFS patients without a control group in which symptoms and function improved in 22 patients (69%), with improvement maintained at 3 months follow-up. In a Sydney, Australia, controlled trial, fatigue, depression, and functional ability improved with CBT, but the improvement was no greater among participants than in the control group. A Boston research team reported fibromyalgia symptoms improved in 67% of participants in an SRT/CBT program compared with improvements in 40% of controls. The review also notes fluoxetine (20 mg per day for 8 weeks) has been shown to improve functioning and decrease pain in CFS patients, bupropion (300 mg per day for 8 weeks) was successful in persons who did not respond to fluoxetine, and a controlled trial of Ampligen-poly(I)poly(C,,U) shows promise. Listed harms include increased pain or fatigue after exercise, increased pain if stretching is introduced too early, and side effects for fluoxetine, nimodipine, and Kutapressin.

  23. Psychiatric management of PVFS.1991 · review
    Summary

    This review examined psychiatric management of post-viral fatigue syndrome/CFS rather than reporting one new trial. It described an open trial at the National Hospital in which 32 patients with CFS were treated with cognitive behaviour therapy; there was significant improvement in symptoms and functioning for 22/32 (69%), maintained at 3 months follow up. In that study 5 patients dropped out before treatment was completed, and One patient who completed treatment was clearly worse at the end; depressive disorder and attributing symptoms to physical rather than psychological factors predicted poor response. The review also described Strauss’s double blind placebo controlled acyclovir trial, which failed to demonstrate an effect greater than placebo; two acyclovir treated patients developed reversible renal failure. An uncontrolled study of combined antidepressant drug and psychological treatment was said to have produced promising results. The review states there are no controlled trials of antidepressants in CFS, only anecdotal reports. It notes clinical experience suggesting limited tolerance of side effects in CFS. The authors state the National Hospital study had no control group or independent outcome assessments and that its design could not distinguish antidepressant from psychological treatment effects. Treatment duration was not reported.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime